Track Gilead Sciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Gilead Sciences, Inc. GILD · Stock Open Gilead Sciences, Inc. in new tab

168.08 USD
P/E
17.70
EPS
-3.13
Yield
1.93%
Safety Score
50
P/B
16.00
ROE
-22.45
Beta
0.37
Target Price
174.77 USD
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

🧾 Earnings Recap – Q3 2026

Gilead’s shares rose 3.1% after earnings, with investors responding to 16% year-over-year growth in base business sales and a $1.6 billion increase to 2026 base business revenue guidance over the course of the year. The quarter’s growth was led by HIV, though some of the sequential HIV sales increase reflected inventory dynamics that management expects to normalize by year-end.

  • Total product sales excluding Veklury were $8.2 billion, up 16% year-over-year and 8% sequentially; including Veklury, sales were $8.3 billion, up 13% year-over-year.
  • HIV sales rose 18% to $6.2 billion. Biktarvy sales increased 10% to $4.1 billion and reached 53% U.S. treatment market share; favorable inventory dynamics contributed to sales growth.
  • HIV prevention sales nearly doubled year-over-year. Yeztugo and Descovy for PrEP together held 50% market share and a $4 billion annual run rate, according to management.
  • Trodelvy sales grew 42% year-over-year, reaching an approximately $2 billion annual run rate; Livdelzi also contributed to base business growth.
  • Management said the HIV treatment market had not returned to its typical 2%–3% growth, although it had shown signs of stabilization. The completed Biktarvy Medicare price determination is expected to affect revenue in 2028.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 9, 2027
P/E17.70
EPS-3.13
Book Value10.51
Price to Book16.00
Debt/Equity202.46
% Insiders0.292%
Growth
Revenue Growth0.07%
Earnings Growth-0.20%
Estimates
Forward P/E16.59
Forward EPS10.13
Target Mean Price174.77
Dividend
Dividend Yield1.93%
Annual dividends3.25 USD
Ex-Div. DateDec. 15, 2026
Payout-106.19%
5y avg Yield3.96%

DCF valuation

Model fair value for Gilead Sciences, Inc. (GILD)
Result
Sign in to run the valuation for GILD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
26 analysts · consensus Buy · mean target 174.77 USD (low 131.00, high 200.00) · as of 15 Nov 2026
Low 131.00
Mean 174.77
High 200.00
Price 168.08
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Gilead Sciences, Inc. Logo Gilead Sciences, Inc. Analysis (GILD)

United States Health Care Official Website Stock

Is Gilead Sciences, Inc. a good investment? Gilead Sciences, Inc. (GILD) is currently trading at 168.08 USD. Market analysts have a consensus price target of 174.77 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 17.70. This valuation is generally in line with the broader market.

Earnings Schedule: Gilead Sciences, Inc. is expected to release its next earnings report on Feb. 9, 2027. The market consensus estimate for Forward EPS is 10.13.

For income investors, Gilead Sciences, Inc. pays a dividend yield of 1.93%. With a payout ratio of -106%, the dividend appears sustainable.

Investor FAQ

Does Gilead Sciences, Inc. pay a dividend?

Yes, it pays an annual dividend of 3.25 USD (1.93% yield).

What asset class is Gilead Sciences, Inc.?

Gilead Sciences, Inc. is classified as a Stock. You can compare it against 11 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 9, 2027. The company currently has a trailing EPS of -3.13.

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Exchange Ticker
US3755581036
FRA (Germany) GIS.F
MIL (Italy) GILD.MI
VIE (Austria) GILD.VI
SGO (Chile) GILD.SN
MEX (Mexico) GILD.MX
GER (Germany) GIS.DE
BUE (Argentina) GILD.BA
NMS (United States) GILD
SAO (Brazil) GILD34.SA
MIL (Italy) GIS.MI
Trades
Dividend Yield
1.93%
5y avg 3.96%
Annual Dividends
3.25USD
Next Ex. Div Date
Dec. 15, 2026
Payout Ratio
-106.19%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
2.54 USD
Sept. 29, 2027 (estimated) 0.8459
June 29, 2027 (estimated) 0.8459
March 30, 2027 (estimated) 0.8459
▸2026
3.28 USD
Dec. 30, 2026 0.8200
Sept. 29, 2026 0.8200
June 29, 2026 0.8200
March 30, 2026 0.8200
▸2025
3.16 USD
Dec. 30, 2025 0.7900
Sept. 29, 2025 0.7900
June 27, 2025 0.7900
March 28, 2025 0.7900
▸2024
3.08 USD
Dec. 30, 2024 0.7700
Sept. 27, 2024 0.7700
June 27, 2024 0.7700
March 28, 2024 0.7700
▸2023
3.00 USD
Dec. 28, 2023 0.7500
Sept. 28, 2023 0.7500
June 29, 2023 0.7500
March 30, 2023 0.7500
▸2022
2.92 USD
Dec. 29, 2022 0.7300
Sept. 29, 2022 0.7300
June 29, 2022 0.7300
March 30, 2022 0.7300
▸2021
2.84 USD
Dec. 30, 2021 0.7100
Sept. 29, 2021 0.7100
June 29, 2021 0.7100
March 30, 2021 0.7100
▸2020
2.72 USD
Dec. 30, 2020 0.6800
Sept. 29, 2020 0.6800
June 29, 2020 0.6800
March 30, 2020 0.6800
▸2019
2.52 USD
Dec. 30, 2019 0.6300
Sept. 27, 2019 0.6300
June 27, 2019 0.6300
March 28, 2019 0.6300
▸2018
2.28 USD
Dec. 28, 2018 0.5700
Sept. 27, 2018 0.5700
June 28, 2018 0.5700
March 29, 2018 0.5700
▸2017
2.08 USD
Dec. 28, 2017 0.5200
Sept. 28, 2017 0.5200
June 29, 2017 0.5200
March 30, 2017 0.5200
▸2016
1.84 USD
Dec. 29, 2016 0.4700
Sept. 29, 2016 0.4700
June 29, 2016 0.4700
March 30, 2016 0.4300
▸2015
1.29 USD
Dec. 30, 2015 0.4300
Sept. 29, 2015 0.4300
June 29, 2015 0.4300
Upcoming Dividends
Name Payment Date Status Amount
Gilead Sciences, Inc. Dec 30, 2026 Upcoming 0.82 USD
Gilead Sciences, Inc. Sep 29, 2026 0.82 USD
Gilead Sciences, Inc. Jun 29, 2026 0.82 USD
Gilead Sciences, Inc. Mar 30, 2026 0.82 USD
Gilead Sciences, Inc. Dec 30, 2025 0.79 USD
Stock Splits
Split Date Split Ratio to 1
Feb. 22, 2001 2:1
March 8, 2002 2:1
Sept. 7, 2004 2:1
June 25, 2007 2:1
Jan. 28, 2013 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion